Patients with severe, asymptomatic aortic stenosis (AS) benefit from early transcatheter aortic valve replacement (TAVR) regardless of baseline biomarker levels, but these benefits are more pronounced in patients with lower levels of biomarkers, a sub-analysis of the EARLY TAVR trial shows.
At 1-year, minimal stent area does not increase, and target vessel failure does not decrease, with the use of routine orbital atherectomy pre-drug-eluting stent (DES) implantation compared with using a balloon angioplasty approach in patients with severely calcified lesions, the ECLIPSE trial shows.
Acute valve syndrome (AVS) plus delayed aortic valve replacement (AVR) is associated with a higher risk of death, stroke or heart failure hospitalization (HFH) in patients with severe aortic stenosis (AS) within 2 years after the procedure, compared with early transcatheter aortic valve replacement (TAVR), a sub-analysis of the EARLY-TAVR trial shows.
Patients with coronary artery disease (CAD) who receive colchicine have lowered total plaque volume 1-year post-coronary computed tomography angiography (CCTA) compared with placebo, and both treatments have similar amounts of low attenuation plaque, a new analysis shows.
Electronic provider notifications (EPN) have a significant impact on rates of aortic valve replacement (AVR) in patients with severe, symptomatic aortic stenosis (AS), including improved survival times and narrowing disparity gaps, data from the DETECT AS trial show.
Patients at high-risk for ischemic events after percutaneous coronary intervention (PCI) who take clopidogrel post-procedure have significantly better outcomes than patients who take aspirin, new data from the SMART-CHOICE 3 trial show.
Patients with 3 vessel coronary artery disease (CAD) have similar outcomes in the composite of death, stroke and myocardial infarction (MI) when undergoing fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), 5-year results from the FAME-3 trial show.
At 2-years, tricuspid transcatheter edge-to-edge repair (TEER) is safe and significantly reduces the severity of tricuspid regurgitation (TR) and rates of heart failure hospitalization (HFH) compared to medical therapy alone in patients with severe, symptomatic tricuspid regurgitation.
Fractional flow reserve (FFR) guidance is noninferior to intravascular ultrasound (IVUS) guidance regarding 12-month clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), data from the FLAVOUR II trial shows.
Patients who are treated with either transcatheter aortic valve replacement (TAVR) with Evolut or surgical AVR (SAVR) for aortic stenosis (AS) have comparable rates of all-cause death or disabling stroke at 5-years, results from the Evolut Low Risk trial show.
Bailey G. Salimes, CRTonline.org
Michael Mahmoudi, MD - D van Ginkel, et al.; TAVI. NEJM 2025; 392:438-449
Michael Mahmoudi, MD - S Jolly, et al.; NEJM 2025; 392:643-652
Michael Mahmoudi, MD - S Jolly et al.; NEJM 2025; 392:633-642
Michael Mahmoudi, MD - P Generreux, et al.; NEJM 2025; NEJM 2025; 392:217-227
PRNewswire
GLOBE NEWSWIRE
Do you believe hospitals are doing enough to protect staff from radiation in the cardiac catheterization lab?
Yes
No
Magdi Zordok, Kevin G. Buda, Mohamad Etiwy, Mir B. Basir, Khaldoon Alaswad, Erik Beckmann, Emmanouil S. Brilakis and Michael Megaly
Tomoharu Dohi, Takayuki Ishihara, Hirota Kida, Daisuke Nakamura, Atsushi Kikuchi, Tsutomu Kawai, Naoki Mori, Naotaka Okamoto, Yasunori Ueda, Ryu Shutta, Minoru Ichikawa, Toshiaki Mano, Tetsuya Watanabe, Yoshiharu Higuchi, Masami, Nishino, Eisuke Hida, Tomoharu Sato, Shungo Hikoso, Daisaku Nakatani, Yohei Sotomi and Yasushi Sakata
Robert S. Zhang, Eugene Yuriditsky, Peter Zhang, Hannah P. Truong, Yuhe Xia, Muhammad H. Maqsood, Allison A. Greco, Vikramjit Mukherjee, Radu Postelnicu, Nancy E. Amoroso, Thomas S. Maldonado, Carlos L. Alviar, James M. Horowitz and Sripal Bangalore
Adhvithi Pingili, Lakshmi Sai Meghana Kodali, Mounika Reddy Vadiyala, Lida Koskina, Bhavin A. Patel, Koushik Sanku, Rupak Desai and Meera Kondapaneni
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details